Upgrade to SI Premium - Free Trial

ChemoCentryx (CCXI)

10.29 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- M&A (12/31/22 *Est)

Latest Headlines

AMGEN names Thomas Dittrich as new CFO as Peter Griffith retires May 19, 2026 4:05 PM - StreetInsider AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH May 19, 2026 4:05 PM - PR NewsWire AMGEN announces $300 million US manufacturing investment May 4, 2026 9:01 AM - StreetInsider AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR May 4, 2026 9:00 AM - PR NewsWire /C O R R E C T I O N -- Amgen/ April 30, 2026 7:03 PM - PR NewsWire AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS April 30, 2026 4:01 PM - PR NewsWire AMGEN announces CTO David Reese retirement and leadership changes April 22, 2026 4:00 PM - StreetInsider AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER April 22, 2026 4:00 PM - PR NewsWire N/a April 6, 2026 9:00 AM - StreetInsider AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE April 6, 2026 9:00 AM - PR NewsWire REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS March 28, 2026 4:45 PM - PR NewsWire Full Article List